Last reviewed · How we verify

18F-fluoromethylcholine

Queen's Medical Center · Phase 2 active Small molecule

PET imaging agent for prostate cancer

PET imaging agent for prostate cancer Used for Prostate cancer.

At a glance

Generic name18F-fluoromethylcholine
Also known asfluorine-18 fluoromethylcholine, 18F-fluorocholine, 18F-choline, FCH
SponsorQueen's Medical Center
Drug classRadioligand
TargetCholine kinase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

18F-fluoromethylcholine is a radioligand used for positron emission tomography (PET) imaging of prostate cancer.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: